Mounjaro and gym results: what TikTok gets wrong about tirzepatide and body composition

What did @pretii.buk actually say?

Honestly? Not much that can be fact-checked. The transcript from this video reads like song lyrics or a personal monologue: "I'm only my perfect human I'm made by what feels what I think" and "Baby, you can't do it all." There are no explicit claims about Mounjaro, GLP-1 drugs, dosing, weight loss results, or anything clinical. The health-relevant content here is almost entirely in the hashtags, not the words.

The hashtags tell a more pointed story. #mounjarouk places this squarely in the UK tirzepatide conversation, and #gymbody suggests a body composition angle. But hashtagging a drug and posting a lifestyle video is not the same as making a medical claim. Viewers drawn in by those tags may reasonably expect Mounjaro-related content, which creates its own kind of implicit framing even when nothing is directly stated.

Does the science back this up?

There is nothing specific to evaluate here in terms of stated claims. But since the hashtags invoke Mounjaro UK, it is worth grounding what the actual evidence says about tirzepatide in a UK context. The short answer: the clinical data is genuinely strong, but the social media framing around it often oversimplifies.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at 15mg produced a mean body weight reduction of around 20.9% over 72 weeks in adults with obesity. That is a real, peer-reviewed result from a randomised controlled trial. The SURMOUNT-2 trial extended findings to people with type 2 diabetes, though weight loss was somewhat lower. In the UK, Mounjaro received NICE approval for weight management in adults with a BMI of 35 or above alongside at least one weight-related condition, under specific prescribing criteria. These are not minor caveats. They define who the drug is actually intended for.

What did they get wrong (or right)?

This is a strange one to score. @pretii.buk did not make any verifiable health claims, which means they cannot be directly wrong about the pharmacology of tirzepatide, drug interactions, or expected outcomes. That is, in a backhanded way, a pass. No misinformation was actively spread in the spoken words.

What is harder to defend is the implicit association. Content tagged with a prescription medication name and a physique-focused hashtag reaches an audience that may already be researching or using GLP-1 drugs. Research on health misinformation spread (Suarez-Lledo and Alvarez-Galvez, 2021, Journal of Medical Internet Research) consistently shows that implicit endorsement through aesthetic lifestyle framing can shape health behaviour even without explicit claims. The video does not give you bad information. It just gives you almost no information while borrowing the credibility of a regulated drug's name. That is a meaningful distinction, not a minor one.

What should you actually know?

If you landed here because of the #mounjarouk tag, here is what actually matters. Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is a different mechanism from semaglutide. It requires a prescription in the UK and should only be initiated under medical supervision. It is not a gym supplement, and weight changes on tirzepatide occur regardless of exercise status, though combining it with resistance training has shown benefits for preserving lean mass (Wilding et al., 2023, Diabetes, Obesity and Metabolism).

Side effects including nausea, vomiting, and gastrointestinal discomfort are common, especially during dose escalation. These are not rare edge cases. In SURMOUNT-1, over 80% of participants on the highest dose reported at least one gastrointestinal adverse event. Anyone seeing polished gym content tagged with Mounjaro and assuming it is a smooth, side-effect-free experience is working from an incomplete picture. The drug can be genuinely effective for eligible patients. It is also a real medication with real considerations, not an aesthetic accessory.